Conferences IDWeek 2014
Other Infections
IDWeek 2014: Hepatitis B Relapse Is Common After Stopping Antiviral Therapy
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 04 November 2014 00:00
- Written by Liz Highleyman
Hepatitis B virus (HBV) rebounded in nearly 80% of people treated with fully or partially suppressive antiviral therapy using adefovir (Hepsera), entecavir (Baraclude), lamivudine (Epivir), or tenofovir (Viread), indicating that long-term therapy is usually needed to control the virus, researchers reported at IDWeek 2014 last month in Philadelphia.
IDWeek 2014: Syphilis Cases Increase Among Men with HIV Despite Risk Reduction Counseling
- Details
- Category: Syphilis
- Published on Tuesday, 28 October 2014 00:00
- Written by Theo Smart
There has been a substantial increase in the number of syphilis cases among men living with HIV -- particularly men who have sex with men (MSM) -- despite systematic risk reduction counseling in this population since 2008, according to a study conducted at a clinic in rural Pennsylvania presented at IDWeek 2014 earlier this month.
IDWeek 2014: Study Shows HIV/HCV Coinfected Women Have Lower Bone Density
- Details
- Category: HIV/HCV Coinfection
- Published on Wednesday, 22 October 2014 00:00
- Written by Theo Smart
ART-treated women with HIV/HCV coinfection have greater deficits in some structural bone parameters compared to women with HIV only, HCV only, or neither virus, according to the results of a cross-sectional study presented at IDWeek 2014 last week in Philadelphia. Among women with HCV, bone loss was most profound in those with stage 3-4 liver fibrosis or cirrhosis, which adversely effects bone health.
IDWeek 2014: Acute Retroviral Syndrome Linked to Higher HIV Levels in Blood, Gut and Brain
- Details
- Category: HIV-Related Conditions
- Published on Tuesday, 28 October 2014 00:00
- Written by Liz Highleyman
People with acute or very recent HIV infection who experience the flu-like symptoms of acute retroviral syndrome (ARS) have higher levels of HIV RNA and proviral DNA in their blood, colon, and brain tissue, indicating more active viral replication, as well as higher levels of certain inflammatory biomarkers researchers reported at IDWeek 2014 this month in Philadelphia.
IDWeek 2014: HIV/HCV Coinfected People Do Not Have Poorer CD4 Cell Recovery
- Details
- Category: HIV/HCV Coinfection
- Published on Wednesday, 22 October 2014 00:00
- Written by Liz Highleyman
Among HIV positive people on suppressive antiretroviral therapy (ART), hepatitis C virus (HCV) coinfection was not associated with significantly lower CD4 T-cell or B-cell gains, according to study findings presented at IDWeek 2014 last week in Philadelphia.
IDWeek 2014: HIV and Hepatitis B Coinfection Linked to Hip Fractures
- Details
- Category: HIV/HBV Coinfection
- Published on Wednesday, 22 October 2014 00:00
- Written by Liz Highleyman
People with HIV/HBV coinfection being treated for both diseases had a significantly higher risk of hip fractures than patients with HIV alone or neither virus, according to research presented at IDWeek 2014 last week in Philadelphia.
IDWeek 2014: NNRTIs and Protease Inhibitors Both Good for First ART, Channeling Affects Choices
- Details
- Category: Approved HIV Drugs
- Published on Friday, 17 October 2014 00:00
- Written by Liz Highleyman
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) and boosted protease inhibitors work equally well for people starting HIV treatment for the first time, with similar viral suppression, CD4 cell gains, and disease progression, according to a large meta-analysis presented at IDWeek 2014 last week in Philadelphia. A related study shed light on factors affecting choice of initial antiretroviral regimen.
IDWeek 2014: Earlier Treatment, NNRTI Use Predict Slower HIV Rebound After Stopping ART
- Details
- Category: Approved HIV Drugs
- Published on Wednesday, 22 October 2014 00:00
- Written by Liz Highleyman
HIV viral load usually begins to rise again within 4 to 8 weeks after stopping antiretroviral therapy (ART), though starting treatment earlier in the course of infection and using a non-nucleoside reverse transcriptase inhibitor (NNRTI) may delay viral rebound, according to study findings presented at IDWeek 2014 last week in Philadelphia.
IDWeek 2014: Longer Use, Age, Low Body Weight Raise Risk of Tenofovir Kidney Problems
- Details
- Category: Approved HIV Drugs
- Published on Friday, 17 October 2014 00:00
- Written by Liz Highleyman
Abnormal kidney biomarkers are common but rarely progress to serious kidney dysfunction in HIV positive people taking tenofovir, and longer duration of use, older age, and having diabetes or high blood pressure raise the risk, researchers reported at IDWeek 2014 last week in Philadelphia. A related study found that people with low body weight experienced progressive kidney function decline while taking tenofovir.
More Articles...
- IDWeek 2014: Age, Sex, and Race Predict Spontaneous Hepatitis C Virus Clearance
- IDWeek 2014: Efavirenz Not Linked to Suicide in Analysis of Insurance Records
- IDWeek 2014: Complera Matches Atripla for Women Starting HIV Treatment
- IDWeek 2014: Behavioral and Financial Incentives May Improve HIV Treatment Outcomes
- IDWeek 2014: AbbVie 3D HCV Regimen Well-tolerated in PEARL Trials
- IDWeek 2014: Sofosbuvir/Ledipasvir Safe and Effective for Genotype 1 HCV
- IDWeek 2014: HIV Attachment Inhibitor BMS-663068 Works Well Across Patient Subgroups
- IDWeek 2014: Social Network Strategies Encourage HIV Testing
- IDWeek 2014: HIV Care Cascade at Kaiser Permanente Varies by Sex and Age
Web Design and Development by